Literature DB >> 35920918

Clinical significance and interrelations of PD-L1 expression, Ki-67 index, and molecular alterations in sporadic medullary thyroid carcinoma from a Chinese population.

Yanhua Bai1, Ting Guo2, Dongfeng Niu3, Yanli Zhu3, Wenhao Ren3, Qian Yao3, Xiaozheng Huang3, Qin Feng3, Tianxiao Wang4, Xiuli Ma3, Xinqiang Ji5.   

Abstract

Immunotherapy shows prospects in treating advanced medullary thyroid carcinoma although controversial reports are present. Recently, histological grading has been applied to medullary thyroid carcinoma by the Ki-67 index, mitotic figures, and tumor necrosis. However, the interrelation of PD-L1 expression, the Ki-67 index, and major genetic alterations of sporadic medullary thyroid carcinoma has not been fully reported. We examined the expression of PD-L1 (SP142 and 22C3) and the Ki-67 index immunohistologically and detected the major genetic alterations by next-generation sequencing in a cohort of sporadic medullary thyroid carcinomas, studied their survival impact, and discussed their interrelation. We identified that a high Ki-67 index (> 2%) and positive RET M918T mutation were correlated with poor disease-free survival but were not correlated with PD-L1 expression. All PD-L1 positive tumors were RET M918T mutation negative, and PD-L1 expression was positively correlated with HRAS mutation. The Ki-67 index was correlated with neither PD-L1 expression nor major genetic alterations. Our results indicate that immunotherapy targeting PD-L1/PD-1 might be more effective for patients with sporadic medullary thyroid carcinoma harboring HRAS mutations.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Ki-67 index; Medullary thyroid carcinoma; PD-L1; RAS; RET

Year:  2022        PMID: 35920918     DOI: 10.1007/s00428-022-03390-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  29 in total

1.  High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Authors:  Margarida M Moura; Branca M Cavaco; António E Pinto; Valeriano Leite
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years.

Authors:  Reese W Randle; Courtney J Balentine; Glen E Leverson; Jeffrey A Havlena; Rebecca S Sippel; David F Schneider; Susan C Pitt
Journal:  Surgery       Date:  2016-11-11       Impact factor: 3.982

4.  Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

Authors:  Raffaele Ciampi; Caterina Mian; Laura Fugazzola; Barbara Cosci; Cristina Romei; Susi Barollo; Valentina Cirello; Valeria Bottici; Giulia Marconcini; Pelizzo Maria Rosa; Maria Grazia Borrello; Fulvio Basolo; Clara Ugolini; Gabriele Materazzi; Aldo Pinchera; Rossella Elisei
Journal:  Thyroid       Date:  2012-12-16       Impact factor: 6.568

5.  Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.

Authors:  S Dvorakova; E Vaclavikova; V Sykorova; J Vcelak; Z Novak; J Duskova; A Ryska; J Laco; J Cap; D Kodetova; R Kodet; L Krskova; P Vlcek; J Astl; D Vesely; B Bendlova
Journal:  Mol Cell Endocrinol       Date:  2008-01-08       Impact factor: 4.102

6.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Authors:  Rossella Elisei; Barbara Cosci; Cristina Romei; Valeria Bottici; Giulia Renzini; Eleonora Molinaro; Laura Agate; Agnese Vivaldi; Pinuccia Faviana; Fulvio Basolo; Paolo Miccoli; Piero Berti; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

7.  High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

Authors:  Michele Simbolo; Caterina Mian; Susi Barollo; Matteo Fassan; Andrea Mafficini; Diogo Neves; Maria Scardoni; Gianmaria Pennelli; Massimo Rugge; Maria Rosa Pelizzo; Elisabetta Cavedon; Laura Fugazzola; Aldo Scarpa
Journal:  Virchows Arch       Date:  2014-05-15       Impact factor: 4.064

Review 8.  Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.

Authors:  Mehdi Hedayati; Marjan Zarif Yeganeh; Sara Sheikholeslami; Farinaz Afsari
Journal:  Crit Rev Clin Lab Sci       Date:  2016-01-27       Impact factor: 6.250

9.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.

Authors:  R M Hofstra; R M Landsvater; I Ceccherini; R P Stulp; T Stelwagen; Y Luo; B Pasini; J W Höppener; H K van Amstel; G Romeo
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

10.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.